Compare NBY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBY | BOLD |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 36.5M |
| IPO Year | 2007 | 2024 |
| Metric | NBY | BOLD |
|---|---|---|
| Price | $1.95 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 608.2K | 130.8K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | 32.47 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.96 |
| 52 Week High | $19.95 | $1.68 |
| Indicator | NBY | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 48.89 |
| Support Level | $1.01 | $1.42 |
| Resistance Level | $2.52 | $1.55 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 96.45 | 20.75 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.